SCHEMBL4710109

SCHEMBL4710109

Cc1ccc(C#Cc2cccc(F)c2)nc1

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 11/20 0.55
SLC6A2 P23975 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12017612 0.81 GRM5 (0.50) GRM5
SCHEMBL14059609 0.80 GRM5 (0.49) GRM5
SCHEMBL3955825 0.80 GRM5 (0.54) GRM5
SCHEMBL30833070 0.80 GRM5 (0.54) GRM5
SCHEMBL3955131 0.79 GRM5 (0.65) GRM5
Hydrochloric Acid SCHEMBL4309309 0.78 GRM5 (0.53) GRM5
SCHEMBL10091168 0.78 CA12 (0.57) GRM5SLC6A2
SCHEMBL17369649 0.78 GRM5 (0.44) GRM5
SCHEMBL12884288 0.77 GRM5 (0.44) GRM5
SCHEMBL4710380 0.77 GRM5 (0.64) GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP claimed
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed